1) World Health Organization. “Hepatitis C. Fact sheet Number 164.” July 2012.
http://www.who.int/mediacentre/factsheets/fs164/en/
2) 財団法人ウイルス肝炎研究財団. C型肝炎について（一般的なQ&A） http://www.vhfj.or.jp/06.qanda/about_ctype.html#syou44
3) 日本肝臓学会 肝炎診療ガイドライン作成委員会. C型肝炎治療ガイドライン（第1.1版）
2013年8月
4) Kobayashi M, Ikeda K, Hosaka T, et al. Natural History of Compensated Cirrhosis in the Child Pugh Class A Compared Between 490 Patients With Hepatitis C and 167 With B Virus Infections.
Journal of Medical Virology. 2006; 78: 459-465.
5) Ikeda K, Saitoh S, Arase Y, et al. Effect of Interferon Therapy on Hepatocellular Carcinogenesis in Patients With Chronic Hepatitis Type C: A Long-Term Observation Study of 1,643 Patients Using Statistical Bias Correction With Proportional Hazard Analysis. Hepatology. 1999; 29 (4):
1124-1130.
6) 大臣官房統計情報部人口動態・保健社会統計課. 平成23年（2011）人口動態統計（確定数）
の概況
7) 日本肝臓学会. 慢性肝炎・肝硬変の診療ガイド2011
8) 日本肝癌研究会追跡調査委員会. 第18回全国原発性肝癌追跡調査報告（2004～2005）肝臓. 2010; 51(8): 460-484.
9) Yoshizawa H, Tanaka J, Miyakawa Y. National Prevention of Hepatocellular Carcinoma in Japan Based on Epidemiology of Hepatitis C Virus Infection in the General Population. Intervirology.
2006; 49: 7–17.
10) 八橋 弘. わが国のC型肝炎の現状 日本の肝癌は、なぜ多いのか. 日本消化器病学会誌. 2004; 101: 578-584.
11) Hamada H, Yatsuhashi H, Yano K, et al. Impact of Aging on the Development of Hepatocellular Carcinoma in Patients with Posttransfusion Chronic Hepatitis C. Cancer. 2002; 95: 331-339.
12) 日野 啓輔. 検診等により見出されたHBV、HCVキャリアの医療機関受診状況に関する全 国調査 厚生労働科学研究費補助金（肝炎等克服緊急対策研究事業）「肝炎状況・長期予後 の疫学に関する研究」平成19年度 分担研究報告
13) Tarao K, Fujiyama S, Ohkawa S, et al. Ursodiol Use Is Possibly Associated with Lower Incidence of Hepatocellular Carcinoma in Hepatitis C Virus–Associated Liver Cirrhosis. Cancer
Epidemiology, Biomarkers & Prevention. 2005; 14(1): 164–169.
14) Kumada H. Long-Term Treatment of Chronic Hepatitis C with Glycyrrhizin [Stronger Neo-Minophagen C (SNMC)] for Preventing Liver Cirrhosis and Hepatocellular Carcinoma.
Oncology 2002; 62(suppl 1): 94–100.
15) Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology. 1999; 29(4): 1124-1130.
16) Yoshida H, Arakawa Y, Sata M, et al. Interferon Therapy Prolonged Life Expectancy Among Chronic Hepatitis C Patients. Gastroenterology. 2002; 123: 483-491.
17) ペグイントロン® 添付文書 2012年11月改訂（第12版）
18) ペガシス® 添付文書 2011年9月改訂（第15版）
19) 平成24年度厚生労働省厚生科学研究費肝炎等克服緊急対策研究事業（肝炎分野）ウイルス 性肝炎における最新の治療法の標準化を目指す研究班. 平成25年B型C型慢性肝炎・肝硬 変治療のガイドライン.
20) Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection. The New England Journal of Medicine. 2011; 364(25): 2405-2416.
21) Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. The New England Journal of Medicine. 2011; 364(25): 2417-2428.
22) Hayashi N, Okanoue T, Tsubouchi H, et al. Efficacy and safety of telaprevir, a new protease
inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. Journal of viral hepatitis.
2012; 19: e134-e142.
23) Akuta N, Suzuki F, Seko Y, et al. Determinants of response to triple therapy of telaprevir,
peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1. Journal of Medical Virology. 2012; 84: 1097-1105.
24) Kumada H, Toyota J, Okanoue T, et al. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. Journal of Hepatology. 2012; 56: 78-84.
25) テラビック® 添付文書 2013年3月改訂（第6版）
26) 長尾 由美子、佐田 道夫、鈴木 史雄等. 優れた薬物療法のさらなる普及をめざして－C型 肝炎ウイルス感染者におけるインターフェロン療法受療の現状と考察－ 医薬産業政策研 究所 リサーチペーパー・シリーズ 2006; 32.
27) AI444089 Clinical study Report: Treatment patterns, tolerability issues, and treatment-related burden among patients with hepatitis C in Japan. Bristol-Myers Squibb Company; 2013. Document Control No. 930072733.
28) Abbott RealTime HCV Genotype II in vitro reverse transcription-polymerase chain reaction (RT-PCR) assay. Jun-2013.
29) Pearlman BL, Traub N. Sustained Virologic Response to Antiviral Therapy for Chronic Hepatitis C Virus Infection: A Cure and So Much More. Clinical Infectious Diseases. 2011; 52(7): 889-900.
30) United States Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry Chronic Hepatitis C Virus Infection: Developing Direct- Acting Antiviral Agents for Treatment. September 2010.
31) McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa- 2b or alfa-2a with ribavirin for treatment of hepatitis C infection. The New England Journal of Medicine. 2009; 361: 580-593.
32) United States Food and Drug Administration, Center for Drug Evaluation and Research: Medical review for Telepravir (Incivek) New Drug Application: Available at
www.accessdata.fda.gov/gov/drugsatfda_docs/nda/2011/201917Orig1s000MedR.pdf - Accessed on 09-Jul-2013.
33) United States Department of Health and Human Services. Advisory Committee Briefing Document for NDA 201-917 Telaprevir 375 mg tablets. Available at
www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiviralDrugs AdvisoryCommittee/UCM252561.pdf - Accessed on 09-Jul-2013.